Amphastar Pharmaceuticals, Inc. (AMPH): Price and Financial Metrics

Amphastar Pharmaceuticals, Inc. (AMPH)

Today's Latest Price: $18.12 USD

0.25 (1.40%)

Updated Nov 27 1:00pm

Add AMPH to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AMPH Stock Summary

  • AMPH's went public 6.43 years ago, making it older than only 23.47% of listed US stocks we're tracking.
  • With a price/earnings ratio of 127.65, Amphastar Pharmaceuticals Inc P/E ratio is greater than that of about 93.76% of stocks in our set with positive earnings.
  • Over the past twelve months, AMPH has reported earnings growth of -81.43%, putting it ahead of only 22.91% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Amphastar Pharmaceuticals Inc are LSCC, ALRM, SEDG, QLYS, and CORT.
  • Visit AMPH's SEC page to see the company's official filings. To visit the company's web site, go to

AMPH Stock Price Chart Interactive Chart >

Price chart for AMPH

AMPH Price/Volume Stats

Current price $18.12 52-week high $22.69
Prev. close $17.87 52-week low $12.32
Day low $17.51 Volume 140,645
Day high $18.34 Avg. volume 255,738
50-day MA $19.59 Dividend yield N/A
200-day MA $18.75 Market Cap 860.77M

Amphastar Pharmaceuticals, Inc. (AMPH) Company Bio

Amphastar Pharmaceuticals focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable and inhalation products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company was founded in 1996 and is based in Rancho Cucamonga, California.

AMPH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$18.12$35.23 92%

Below please find a table outlining a discounted cash flow forecast for AMPH, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Amphastar Pharmaceuticals Inc ranked in the 61th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 93% on a DCF basis. The most interesting components of our discounted cash flow analysis for Amphastar Pharmaceuticals Inc ended up being:

  • The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately merely 18.82% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMPH, try CHE, ANTM, FMS, DVA, and ANIP.

AMPH Latest News Stream

Event/Time News Detail
Loading, please wait...

AMPH Latest Social Stream

Loading social stream, please wait...

View Full AMPH Social Stream

Latest AMPH News From Around the Web

Below are the latest news stories about Amphastar Pharmaceuticals Inc that investors may wish to consider to help them evaluate AMPH as an investment opportunity.

Amphastar Pharmaceuticals (AMPH) Presents at Wells Fargo Securities 2020 Virtual Healthcare Conference - Slideshow

The following slide deck was published by Amphastar Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 11, 2020

Amphastar Pharmaceuticals' (AMPH) Management on Q2 2020 Results - Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Dan Dischner – Vice President of Human Resources and Corporate Communications Bill Peters – Chief Financial Officer Tony Marrs – Senior Vice President of Regulatory Affairs and Clinical Operations Conference Call Participants Tim...

SA Transcripts on Seeking Alpha | August 8, 2020

Amphastar Pharmaceuticals's Earnings: A Preview

On Thursday, August 06, Amphastar Pharmaceuticals (NASDAQ: AMPH) will release its latest earnings report. Benzinga's report can help you figure out the …

Benzinga | August 5, 2020

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6th, 2020

RANCHO CUCAMONGA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2020 ended June 30, 2020, after the market closes on Thursday, August 6th, 2020, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (800) 708-4540, five minutes before the conference. The passcode for the conference call is 49844225.The call can also be accessed on the Investors page on the Company’s website is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high techn...

Yahoo | July 30, 2020

Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2020

Read More 'AMPH' Stories Here

AMPH Price Returns

1-mo -7.27%
3-mo -11.15%
6-mo -2.79%
1-year -2.79%
3-year -0.38%
5-year 17.13%
YTD -6.07%
2019 -3.07%
2018 3.43%
2017 4.45%
2016 29.44%
2015 22.57%

Continue Researching AMPH

Want to see what other sources are saying about Amphastar Pharmaceuticals Inc's financials and stock price? Try the links below:

Amphastar Pharmaceuticals Inc (AMPH) Stock Price | Nasdaq
Amphastar Pharmaceuticals Inc (AMPH) Stock Quote, History and News - Yahoo Finance
Amphastar Pharmaceuticals Inc (AMPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8566 seconds.